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Background: Nerve growth factor (NGF) is a neurotrophin and has been suggested to induce heme oxygenase-1
(HO1) expression. Although the role of HO1 in tumorigenesis remains controversial, recent evidence suggests NGF
and HO1 as tumor-progressing factors. However, the correlative role of NGF and HO1 and their prognostic impact
in breast carcinoma is unknown.
Methods: We investigated the expression and prognostic significance of the expression of NGF and HO1 in 145
cases of breast carcinoma.
Results: Immunohistochemical expression of NGF and HO1 was observed in 31% and 49% of breast carcinoma,
respectively. The expression of NGF and HO1 significantly associated with each other, and both have a significant
association with histologic grade, HER2 expression, and latent distant metastasis. The expression of NGF and HO1
predicted shorter overall survival of breast carcinoma by univariate and multivariate analysis. NGF expression was an
independent prognostic indicator for relapse-free survival by multivariate analysis. The combined expression pattern
of NGF and HO1 was also an independent prognostic indicator of overall survival and relapse-free survival. The
patients with tumors expressing NGF had the shortest survival and the patients with tumor, which did not express
NGF or HO1 showed the longest survival time.
Conclusions: This study has demonstrated that individual expression of NGF or HO1, and the combined NGF/HO1
expression pattern could be prognostic indicators for breast carcinoma patients.
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Nerve growth factor (NGF) is a neurotrophin, which shows
neurotrophic activity on central and peripheral neuronal
cells, and exerts variable effects on non-neuronal cells [1].
In addition to its neurotrophic effect, NGF is also known as
a stimulator of cancer cell proliferation and tumor angio-
genesis, and participates in tumor cell growth and invasion
[1-3]. NGF is involved in the development and progression
of many tumors of neural origin and epithelial tumors such* Correspondence: kyjang@chonbuk.ac.kr
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reproduction in any medium, provided the oras medulloblastoma, glioma, neuroblastoma, melanoma,
pancreas cancer, prostate cancer, and breast carcinoma
(BRCA) [1-4]. The main function of NGF is mediated by
two membranes binding receptors: high affinity tyrosine kin-
ase receptor TrkA and low affinity p75NTR [1-3]. In BRCA,
NGF is shown to act as a mitogen for cancer cells through
phosphorylation of TrkA, and it promotes survival and pro-
liferation of cancer cells [2]. The expression of the NGF re-
ceptor (NGFR) TrkA enhanced the tumorigenic potential of
BRCA in an animal model [5]. In addition, because blocking
of NGF pathway was shown to have tumor-suppressive ef-
fects in BRCA, NGF was suggested as a potential thera-
peutic target for the treatment of BRCA [6-8].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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heme breakdown, generating free iron, carbon monoxide,
and bilirubin [9]. Because of the combined effect of its
products, HO1 acts as a strong antioxidant with anti-
inflammatory, anti-apoptotic, and immunomodulatory
effects [10,11]. Therefore, HO1 is protective against vari-
ous injuries, such as necrotizing enterocolitis [11] and
ischemic-reperfusion injury [12]. However, anti-apoptotic
and cytoprotective roles for chemotherapeutic agents tar-
geting HO1 were shown to induce tumor-progression
[13-15]. Increased expression of HO1 in malignant tissue
compared with normal tissue has been reported in vari-
ous human malignant tumors, such as prostate cancer
[16], oral squamous cell carcinoma [17], and lung cancers
[18,19]. However, there are conflicting reports regarding
the prognostic role of HO1 in human malignant tumors.
High expression of HO1 is associated with poor progno-
sis of non-small cell lung cancer [18]. In contrast, HO1
expression is associated with favorable prognosis of colo-
rectal cancer patients [20] and low risk of lymph node
metastasis in oral squamous cell carcinoma [21]. There-
fore, the role of HO1 in human malignant tumors still re-
mains controversial.
Increasing evidence suggests that NGF and HO1 are in-
volved in tumorigenesis and could therefore be possible
therapeutic targets of human malignant tumors. How-
ever, there are no previous reports examining the clinical
significance of the expression of NGF itself in BRCA pa-
tients. In addition, both NGF and HO1 exert neuropro-
tective effects, and NGF induces HO1 expression via
mitogen-activated protein kinase kinase activation [22] or
in a phosphatidylinositol 3-kinase-dependent manner
[23]. Therefore, there is a possibility that NGF and HO1
are cooperatively involved in the tumorigenesis via their
roles in cellular adaptation to stress and resistance to
apoptosis. However, the relationship between NGF and
HO1 and the role of HO1 in cancer progression is still
unclear in BRCA. Therefore, this study investigated the
correlation between the expression of NGF and HO1 and
their prognostic impact in BRCA.
Methods
Patients and tissue samples
One hundred and forty-five paraffin-embedded tissue
samples from female BRCA patients who underwent
wide local excision or modified radical mastectomy in
Chonbuk National University Hospital from January 1997
to August 2002 were included in the present study. This
study was approved by the institutional review board of
Chonbuk National University Hospital. Informed consent
was provided according to the Declaration of Helsinki.
The mean age at diagnosis of the 145 patients was
46.04 years (range: 22–72 years). Eighty-eight patients
received modified radical mastectomy, and fifty-sevenpatients received breast conserving surgery. One hundred
and twenty-nine patients received systemic adjuvant
chemotherapy [CMF (cyclophosphamide, methotrexate
and fluorouracil 5FU) chemotherapy or anthracycline-
and taxane-based chemotherapy] and 121 patients received
adjuvant endocrine therapy. One hundred and ten patients
received both chemotherapy and endocrine therapy, and 5
patients received no adjuvant therapy. The median follow-
up duration was 144.9 months (range, 7.7 - 192.6). Among
the 145 BRCA patients, 21 patients experienced local
relapse, 33 patients had latent distant metastasis, and 44 pa-
tients died from BRCA at the follow-up endpoint. The
median survival was 192.0 months and the five- and ten-
year survival rates for the entire BRCA patients were 81%
and 74%, respectively. All the cases were reviewed and clas-
sified by two pathologists (KY Jang and SJ Noh) according
to the World Health Organization Classification [24], and
pathologic staging as reviewed in the 7th edition of the
American Joint Committee on Cancer staging system [25].
The histologic diagnoses of 145 cases of BRCA were 137 in-
vasive ductal carcinomas and 8 invasive lobular carcinomas.
The patients were grouped according to the age, TNM stage,
histologic type, modified Bloom and Richardson histologic
grade (tubule and gland formation, nuclear pleomorphism
and mitotic counts) [24], presence of local relapse, distant
metastasis, and immunohistochemical expression of human
epidermal growth factor receptor 2 (HER2), ER and PR.
Immunohistochemical staining and scoring
Immunohistochemical staining was performed using
3.0 mm tumor cores for tissue microarray (TMA). To es-
tablish the TMA, we reviewed all of the H&E slides and
took two 3.0 mm tissue cores from the paraffin-embedded
tissue blocks per case at the area of highest tumor grade.
An antigen retrieval procedure was performed with so-
dium citrate buffer using a microwave oven for 20 minutes.
The following markers were used: NGF (1:200, Abcam,
Cambridge, UK) and HO1 (1:200, Enzo Life Sciences, PA,
USA). Immunohistochemical staining for NGF and HO1
were evaluated by the sum of the staining intensity scores
and the staining area scores in each TMA core [26,27].
The staining intensity was scored as 0 (no staining), 1
(weak staining), 2 (intermediate staining), and 3 (strong
staining). The staining area was scored as 0 (no staining
cells), 1 (1% of the cells stained positive), 2 (2-10% of the
cells stained positive), 3 (11-33% of the cells stained posi-
tive), 4 (34-66% of the cells stained positive), and 5
(66-100% of the cells stained positive). Thereafter, the
combined score (obtained by adding the sum of the scores
of two different TMA cores) was used for further analysis.
The maximum combined score was 16 and the minimum
sum score was zero. Subsequently, the expression of NGF
and HO1 were grouped as positive or negative by receiver
operating characteristic curve analysis at the highest
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tients. The cut-off point for NGF expression was 9 and
was 14 for HO1 expression. The expression of NGF was
considered positive when a combined score was greater or
equal to nine and HO1 expression was considered positive
when a combined score was greater than or equal to four-
teen. HER2 immunostaining was considered positive if
30% or more of the tumor cell showed strong complete
membrane staining. Immunostaining for estrogen recep-
tor (ER) and progesterone receptor (PR) were considered
positive if 1% or more of the tumor cells showed nuclear
staining. Immunohistochemical scoring was performed by
two pathologists (KY Jang and SJ Noh) who were blinded
to the clinicopathologic information of the patients.
Statistical analysis
The relationships between NGF and HO1 expression
and other clinicopathological factors were determined
using the Pearson’s chi-square test. The primary point of
interest was overall survival (OS) and relapse-free sur-
vival (RFS). The follow-up endpoint was the date of
death or the date of last contact through December
2012. OS duration was measured as the time from diag-
nosis to date of death from BRCA and the patients who
were alive at last contact or died from other causes were
treated as censored. RFS was calculated as the time from
diagnosis to the date of relapse, death from BRCA, or
last contact. Patients who were alive at last contact or
died from other causes and who did not experience the
relapse were treated as censored for RFS analysis.
Univariate and multivariate Cox regression hazard ana-
lysis were performed to estimate the impact of clinico-
pathologic factors and expression of each marker on OS
and RFS. Kaplan-Meier survival analysis with a log-rank
test was used to illustrate the cumulative survival curve
for OS and RFS. Statistical analyses were calculated using
SPSS statistical software (IBM, version 18.0, CA, USA).
P-values less than 0.05 were considered to be statistically
significant.
Results
NGF and HO1 expression and its correlations with
clinicopathologic factors of BRCA patients
The expression of NGF and HO1 was seen mainly in the
cytoplasm of tumor cells, and the expression of NGF and
HO1 was grouped positive in 31% (45/145 of cases) and
49% (71/145) of BRCA samples, respectively (Figure 1).
The expression of NGF was significantly associated with
age (P = 0.035), histologic grade (P = 0.020), presence of
latent distant metastasis (P = 0.004), and the expression
of HER2 (P = 0.002) and ER (P = 0.005). Especially, a
strong positive correlation between NGF and HO1 was
found (P < 0.001). The expression of HO1 was signifi-
cantly correlated with age (P = 0.029), histologic grade(P = 0.017), presence of latent distant metastasis (P < 0.001),
and HER2 expression (P < 0.001) (Table 1).
Expression of NGF and HO1 correlates with overall
survival and relapse-free survival in BRCA according to
univariate analysis
Univariate survival analyses of the expression of NGF and
HO1 and clinicopathological factors for OS and RFS are
listed in Table 2. In the 145 BRCA patients, age of the pa-
tients (Log-rank, OS; P < 0.001, RFS; P = 0.017), HER2
expression (Log-rank, OS; P < 0.001, RFS; P < 0.001), NGF
expression (Log-rank, OS; P < 0.001, RFS; P < 0.001), and
HO1 expression (Log-rank, OS; P < 0.001, RFS; P < 0.001)
were significantly associated with shorter OS and RFS
(Figure 2A). The patients with NGF expression had a
4.674-fold (95% CI, 2.541-8.598) greater risk of death
(P < 0.001) and its expression significantly associated with
shorter RFS (P < 0.001, HR; 3.550, 95% CI; 2.074-6.076).
The expression of HO1 predicted shorter OS (P < 0.001,
HR; 6.101, 95% CI; 2.832-13.143) and RFS (P < 0.001, HR;
3.476, 95% CI; 1.914-6.314). TNM stage was significantly
associated with shorter OS (Log-rank, P = 0.010).
We also performed additional survival analysis in the
patients which received adjuvant chemotherapy or endo-
crine therapy. Among the patients who received systemic
adjuvant chemotherapy, HER2 expression (Log-rank, OS;
P < 0.001, RFS; P < 0.001), NGF expression (Log-rank,
OS; P < 0.001, RFS; P < 0.001), and HO1 expression
(Log-rank, OS; P < 0.001, RFS; P < 0.001) were signifi-
cantly associated with shorter OS and RFS (Figure 2B).
The age of the patients (P = 0.001) and TNM stage
(P = 0.003) were significantly associated with shorter OS.
Among the patients who received systemic adjuvant
endocrine therapy, the age of the patients (Log-rank, OS;
P < 0.001, RFS; P = 0.022), the expression of HER2
(Log-rank, OS; P= 0.007, RFS; P= 0.005), NGF (Log-rank,
OS; P < 0.001, RFS; P < 0.001), and HO1 (Log-rank, OS;
P < 0.001, RFS; P < 0.001) were significantly associated with
both OS and RFS (Figure 2C). TNM stage was significantly
associated with shorter OS (Log-rank, P= 0.024).
Thereafter, to investigate the prognostic effect of the
combined expression pattern of NGF and HO1 (NGF/
HO1 expression), we analyzed the prognostic effect of
the expression of one marker in two separate groups ac-
cording to the positivity of another marker. In the NGF-
group, the expression of HO1 significantly associated OS
(Log-rank, P < 0.001) and RFS (Log-rank, P = 0.004)
(Figure 3A). However, HO1 expression did not affect for
the survival of patients in NGF+ group (Log-rank, OS;
P = 0.514, RFS; P = 0.831) (Figure 3B). However, NGF ex-
pression significantly associated with shorter OS of
BRCA patients in both HO- group (Log-rank, OS; P =
0.011, RFS; P < 0.001) and HO1+ (Log-rank, OS; P =
0.045, RFS; P = 0.071) group (Figure 3C and 3D). Based
Figure 1 Immunohistochemical expression of NGF and HO1 in breast carcinoma. Original magnification, x400.
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three groups according to the NGF/HO1 expression
pattern as shown in Figure 4. The NGF/HO1 ex-
pression was significantly associated with shorter OS
(Log-rank, P < 0.001) and RFS (Log-rank, P < 0.001)
(Figure 4A). The NGF-/HO1- group showed favorable
prognosis and the NGF+/anyHO1 group showed the poor-
est prognosis. The ten-year survival rate of the NGF-/HO1-
group, the NGF-/HO1+ group, and the NGF+/anyHO1
groups were 94%, 71%, and 47%, respectively (Figure 4B).
NGF expression, HO1 expression, and NGF/HO1
expression is the independent, unfavorable prognostic
predictor for overall survival in BRCA
The variables significantly associated with OS and RFS
by univariate analysis were considered in the multivari-
ate analysis. The variables considered in the multivariate
analysis were age, TNM stage, histologic grade, and the
expression of HER2, NGF, and HO1. Among the 145
BRCA patients, NGF expression was independent pre-
dictors of shorter OS and RFS. The patients with tumors
expressing NGF had a 2.174-fold (95% CI; 1.073-4.404,
P = 0.031) greater risk of shorter OS and a 3.042-fold
(95% CI; 1.746-5.299, P < 0.001) greater risk of shorter
RFS. The expression of HO1 (P < 0.001, HR; 4.847, 95%
CI; 1.990-11.807) and TNM stage (overall P = 0.002)
were also independent prognostic indicators of OS. The
expression of HER2 was an independent prognosticpredictor of RFS (P = 0.017, HR; 1.980, 95% CI; 1.132-
3.464).To test the impact of the NGF/HO1 expression
pattern on OS and RFS of BRCA patients, multivariate
analysis was performed with the inclusion of NGF/HO1
expression instead of the individual expression of NGF
and HO1. NGF/HO1 expression was also significantly
associated with OS (overall P < 0.001) and RFS (overall
P < 0.001) (Table 3).
Among patients who received chemotherapy, TNM
stage (overall P < 0.001), HO1 expression (P < 0.001), and
NGF/HO1 expression (overall P < 0.001) were the inde-
pendent prognostic predictor of OS. The expression of
HER2 (P = 0.024) and NGF (P < 0.001), and NGF/HO1
expression (overall P < 0.001) were the independent
prognostic indicators of RFS for BRCA patients. Among
patients who received endocrine therapy, the age of the
patients (P = 0.007), TNM stage (P = 0.022), HO1 expres-
sion (P < 0.001), and NGF/HO1 expression (overall P <
0.001) were independent prognostic indicators of OS for
BRCA patients. The expression of HER2 (P = 0.029) and
NGF (P < 0.001), and NGF/HO1 expression (overall P <
0.001) were independent prognostic indicators of RFS
for BRCA patients.
Discussion
In this study, we have investigated the immunohisto-
chemical expression of NGF and HO1 in BRCA patients
and demonstrated that the expression of NGF and HO1
Table 1 Association of the expression of NGF and HO1 with clinicopathological factors
Characteristics No. NGF HO1
Positive P Positive P
Age, y <50 104 27 (26%) 0.035 45 (43%) 0.029
≥50 41 18 (44%) 26 (63%)
TNM stage I 29 9 (31%) 0.836 17 (59%) 0.507
II 97 28 (29%) 45 (46%)
III and IV 19 7 (37%) 9 (47%)
T stage 1 41 10 (24%) 0.424 22 (54%) 0.675
2 95 31 (33%) 44 (46%)
3 and 4 9 4 (44%) 5 (56%)
LN metastasis Absence 83 26 (31%) 0.930 39 (47%) 0.582
Presence 62 19 (31%) 32 (52%)
Latent distant metastasis Absence 112 28 (25%) 0.004 45 (40%) < 0.001
Presence 33 17 (52%) 26 (79%)
Histologic type Ductal 137 43 (31%) 0.704 67 (49%) 0.952
Lobular 8 2 (25%) 4 (50%)
Histologic grade 1 49 9 (18%) 0.020 20 (41%) 0.017
2 67 22 (33%) 30 (45%)
3 29 14 (48%) 21 (72%)
HER2 Negative 105 25 (24%) 0.002 42 (40%) < 0.001
Positive 40 20 (50%) 29 (73%)
ER Negative 65 28 (43%) 0.005 35 (54%) 0.289
Positive 80 17 (21%) 36 (45%)
PR Negative 60 23 (38%) 0.110 34 (57%) 0.119
Positive 85 22 (26%) 37 (44%)
HO1 Negative 74 5 (7%) < 0.001
Positive 71 40 (56%)
Table 2 Univariate Cox proportional hazards regression analysis for overall survival and relapse-free survival
Characteristics No. OS RFS
HR 95% CI P HR 95% CI P
Age, y, ≥ 50 (vs. < 50) 41/145 2.928 1.620-5.293 < 0.001 1.914 1.112-3.295 0.019
TNM stage, I 29/145 1 0.016 1 0.197
II 97/145 2.482 0.874-7.046 0.088 1.386 0.644-2.983 0.403
III and IV 19/145 5.154 1.614-16.457 0.006 2.288 0.902-5.799 0.081
Histologic grade, 1 49/145 1 0.014 1 0.087
2 67/145 1.218 0.575-2.579 0.607 1.147 0.598-2.198 0.680
3 29/145 2.818 1.293-6.139 0.009 2.077 1.027-4.203 0.042
HER2, positive (vs. negative) 40/145 2.765 1.525-5.012 < 0.001 2.596 1.511-4.461 < 0.001
ER, positive (vs. negative) 80/145 0.691 0.382-1.250 0.222 0.911 0.533-1.557 0.733
NGF, positive (vs. negative) 45/145 4.674 2.541-8.598 < 0.001 3.55 2.074-6.076 < 0.001
HO1, positive (vs. negative) 71/145 6.101 2.832-13.143 < 0.001 3.476 1.914-6.314 < 0.001
NGF/HO1, NGF-/HO1- 69/145 1 < 0.001 1 < 0.001
NGF-/HO1+ 31/145 5.019 1.855-13.578 0.001 2.935 1.338-6.436 0.007
NGF+/anyHO1 45/145 9.717 4.003-23.586 < 0.001 5.41 2.754-10.625 < 0.001
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Figure 2 Kaplan-Meier survival analysis according to the expression of NGF and HO1. A. Overall survival (OS) and relapse-free survival (RFS)
in 145 breast carcinoma (BRCA) patients. B. OS and RFS in 129 BRCA patients who received adjuvant chemotherapy. C. OS and RFS in 121 BRCA
patients who received post-operative endocrine therapy.
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http://www.biomedcentral.com/1471-2407/13/516were significantly associated with each other, and both
have a significant association with HER2 expression,
histologic grade, and latent distant metastasis. Moreover,
the expression of NGF and HO1 was associated with
shorter OS and RFS of BRCA by univariate analysis and
multivariate analysis revealed the expression of NGF and
HO1 as an independent prognostic indicator of OS for
BRCA patients. Interestingly, the NGF/HO1 expression
pattern was also a significant prognostic indicator of OS
and RFS of BRCA patients by univariate and multivariate
analysis. Especially, the patients with tumors expressing
NGF had the shortest survival and the NGF-/HO1-
phenotype associated with favorable prognosis. This re-
sult suggests that both NGF and HO1 could be prognos-
tic indicators and potential therapeutic targets for BRCA
patients.
NGF is a neurotrophin, which controls development
and survival of neuronal cells. In addition to its neurotrophiceffect, NGF has been reported to be up-regulated in several
malignant tumors [1,28]. Interestingly, NGF is not detected
in normal breast epithelial cells and is not mitogenic for nor-
mal breast epithelial cells. In contrast, NGF is expressed in
BRCA cells and stimulates growth of BRCA cells via an
autocrine loop [7,29]. NGF stimulates proliferation and
inhibits apoptosis of BRCA cells [2]. The pro-proliferative
role of NGF in BRCA is mediated by activation of TrkA,
p75NTR, and NFkB pathways [2,8]. Furthermore, NGF is in-
volved in BRCA angiogenesis [3]. NGF increases the levels
of secreted vascular endothelial growth factor in both hu-
man umbilical vein endothelial cells and BRCA cell lines [3].
Moreover, the precursor of NGF was overproduced in
BRCA compared with benign breast tissue and involved in
the stimulation of the invasion of BRCA cells [30]. TrkA
overexpression promotes growth, migration, invasion, and
survival of a BRCA cell line, enhances angiogenesis, and
promotes metastasis of BRCA cells in mice [5]. Blocking of
Figure 3 Kaplan-Meier survival analysis between the expression of NGF and HO1. Overall survival (OS) and relapse-free survival (RFS)
according to the expression HO1 in the NGF-negative group (A) and the NGF-positive group (B). OS and RFS according to the expression NGF in
the HO1-negative group (C) and the HO1-positive group (D).
Figure 4 Prognostic significance of the combined expression pattern of NGF and HO1. A. Kaplan-Meier survival analysis for overall survival
and relapse-free survival between the NGF-/HO1-, the NGF-/HO1+, and the NGF+/anyHO1 subgroups of breast carcinoma patients. B. An algorithm
for the sub-grouping of breast carcinoma patients into three sub-groups according to the expression patterns of NGF and HO1. 10 ysr; ten-year
survival rate.
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Table 3 Multivariate Cox proportional hazards regression analysis for overall survival and relapse-free survival
Characteristics OS RFS
HR 95% CI P HR 95% CI P
TNM stage,* I 1 0.002
II 3.542 1.241-10.109 0.018
III and IV 7.933 2.441-25.787 < 0.001
HER2,* positive (vs. negative) 1.98 1.132-3.464 0.017
NGF,* positive (vs. negative) 2.174 1.073-4.404 0.031 3.042 1.746-5.299 < 0.001
HO1,* positive (vs. negative) 4.847 1.990-11.807 < 0.001
NGF/HO1,** NGF-/HO1- 1 < 0.001 1 < 0.001
NGF-/HO1+ 6.542 2.381-17.979 < 0.001 3.5 1.574-7.778 0.002
NGF+/anyHO1 11.206 4.595-27.330 < 0.001 6.011 3.039-11.888 < 0.001
* The variables included in the multivariate analysis were age, TNM stage, and the expression of HER2, NGF, and HO1. ** The variables included in the multivariate
analysis were age, TNM stage, HER2 expression, and the combined expression pattern of NGF and HO1 (NGF/HO1).
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against NGF inhibited tumor growth and metastasis [6] and
inhibitors for TrkA or p75NTR, downstream signaling targets
of NGF, also had pro-apoptotic and anti-proliferative effects
on BRCA cells [8]. The inhibition of the precursor of NGF
by small interfering RNA inhibited invasion activity of
BRCA cells [30]. Therefore, NGF has been suggested as a
potential therapeutic target for the treatment of malignant
tumors, especially in BRCA [6,8]. In our study, high NGF
expression was associated with high histologic grade and the
presence of distant metastasis, and predicted poorer survival
of BRCA patients. The poor prognosis of the patients with
NGF-expressing tumor might be related with the ability of
NGF-TrkA signaling to induce chemoresistance [31]. There-
fore, there is a possibility that NGF-targeted therapy with a
combination of conventional chemotherapy could be helpful
for BRCA patients. In agreement with our findings, the ex-
pression of the NGFRs TrkA and p75NTR was associated
with poor prognosis of pancreatic cancer patients [4]. In
addition, similar results found in a recent report which dem-
onstrated that the expression of NGFR significantly associ-
ated with the higher histologic grade of BRCA, suggesting
the expression of NGFR as a potential indicator of poor
prognosis [32]. In this large cohort study in BRCA, the ex-
pression of NGFR was negatively correlated with the expres-
sion of ER and indicative for the basal-like BRCA or luminal
B subtypes [32]. Our result has shown a negative correlation
between NGF expression and ER expression.
Despite recent advances in diagnosis and treatment
modalities, BRCA remains the second leading cause of
cancer-related death among women [33]. Recently devel-
oped targeted therapies, especially for the HER2, have
led to the improvement of overall outcomes of BRCA
patients [34-36]. Therefore, investigation of HER2 ex-
pression is crucial for the treatment of BRCA patients.
However, the number of BRCA patients who benefit
from targeted therapy is limited. The amplification of
the HER2 gene and overexpression of the HER2 proteinhas been detected in about 25% of BRCA and most patients
with advanced BRCA with HER2 gene amplification devel-
oped resistance to treatment [34,35]. However, the resist-
ance mechanism to anti-HER2 treatments remains largely
unexplained, and a new therapeutic approach for BRCA is
needed. In our study, NGF expression was significantly cor-
related with HER2-positive status and the positivity of both
NGF and HER2 predicted poor survival of BRCA patients.
Similarly, a cooperative role of HER2 and NGF in the pro-
gression of BRCA has been previously reported [37], and
NGF was suggested as a potential therapeutic target of
BRCA [6]. However, when we separately analyzed the prog-
nostic impact of NGF expression according to the ex-
pression status of HER2, NGF expression predicted poor
survival of BRCA patients regardless of the positivity of
HER2. NGF expression predicted poor OS in both the
HER2-negative (Log-rank, P = 0.011) and HER2-positive
subpopulations (Log-rank, P = 0.005). These results sug-
gest the possibility that NGF has mechanism involved in
the progression of BRCA which are independent of
HER2-related mechanisms. Therefore, NGF-targeted
therapy may be beneficial for BRCA patients in addition
to the HER2-based conventional therapy.
In the NGF-TrkA signaling pathway, NGF is also known
as an inducer of HO1 [22,23]. NGF increases HO1 expres-
sion through the receptor tyrosine phosphorylation path-
way, and then HO1 causes the anti-apoptotic effect of
NGF [22]. In neurodegenerative disease models, NGF pro-
tects cells against oxidative stress by inducing HO1
expression in a phosphatidylinositol 3-kinase-dependent
manner [23]. These results suggest that there is a coopera-
tive role between NGF and HO1 in cellular adaptation to
stress and induction of resistance to death. When consid-
ering the tumor-progressing role of NGF, there is a possi-
bility that HO1 is also involved in the progression of
cancers. Our study has also showed a significant correl-
ation between the expression of HO1 and NGF. 89%
(40/45) of NGF-expressing BRCA co-expressed HO1.
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mediated pathways are involved in the progression of
BRCA. However, interestingly, HO1 expression associated
with shorter OS and RFS in the NGF-negative group, but
not in the NGF-positive group. This finding suggests the
possibility that HO1 may have its own role in the progres-
sion of BRCA-independent of an NGF- related mechanism.
The expression of HO1 is increased in various cancer
cells compared with normal cells [17,18,38,39], which is
associated with unfavorable prognosis of cancer patients
[18]. The tumor-progressive role of HO1 is related to its
roles in the inhibition of apoptosis [22], promotion of
tumor angiogenesis [40,41], and chemoresistance [14].
HO1 also augments cancer cell migration and invasion
by inducing MMP-9, CD147, and EGFR [18]. In the
present study, the expression of HO1 was associated with
unfavorable factors, distant metastatic relapse, higher
histologic grade, and positive HER2 expression, and pre-
dicted shorter OS for BRCA patients. However, in con-
trast to our findings, there are conflicting reports that
HO1 inhibits the proliferation and invasiveness of cancer
cells [42-44], and that the expression of HO1 predicted
favorable OS of colon cancer patients [20]. These conflict-
ing findings may be related to the diverse roles of HO1 in
various conditions or the status of the cells during tumori-
genesis. HO1 may be protective for healthy cells in tumor-
inducing injury; however, it could be tumor progressive in
already developed tumors [45]. Therefore, further study is
needed to explore the exact role(s) of HO1 and its possible
correlation with NGF in BRCA tumorigenesis.
Another interesting finding of this study is that the
combined expression pattern of NGF and HO1 is helpful
for the prediction of the prognosis of BRCA patients.
The patients with tumors expressing NGF had the short-
est OS and RFS; furthermore, the patients with tumor
which did not express NGF or HO1 showed the longest
survival time. Multivariate analysis revealed NGF/HO1
expression as an independent prognostic indicator of OS
and RFS. Therefore, this result suggests that the com-
bined expression pattern of NGF and HO1 might be us-
able as a prognostic indicator for BRCA patients.
Conclusions
In summary, the results of this study have shown that
the expression of NGF and HO1 were significantly asso-
ciated with each other and that the expression of both of
them significantly correlated with unfavorable clinico-
pathological factors and predicted shorter survival of
BRCA patients. Therefore, these results suggest the pos-
sibility that the NGF-HO1 pathway may be involved in
breast carcinogenesis and progression. In addition, an al-
gorithm for the sub-grouping of breast carcinoma pa-
tients into three sub-groups according to the expression
patterns of NGF and HO1 also predicted survival ofBRCA patients. Therefore, this result suggests the possi-
bility that individual expression of NGF or HO1, and the
combined expression pattern of NGF and HO1 could be
the new prognostic indicator of BRCA patients.
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